A Surrogacy Agency That Delivered Heartache
By Tamar Lewin,
The New York Times
| 07. 27. 2014
Untitled Document
CANCÚN, Mexico — Rudy Rupak, the founder of Planet Hospital, a medical tourism company based in California, was never shy about self-promotion. Over the last decade he has held forth about how his company has helped Americans head overseas for affordable tummy tucks and hip replacements. And after he expanded his business to include surrogacy in India for Western couples grappling with infertility — and then in Thailand, and last year, Mexico — he increasingly took credit for the global spread of surrogacy.
But now Mr. Rupak is in involuntary bankruptcy proceedings, under investigation by the F.B.I. and being pursued by dozens of furious clients from around the world who accuse him of taking their money and dashing their dreams of starting a family.
The practice of paying a woman to have an embryo transferred to her womb and bear the child for someone else, known as gestational surrogacy, has been growing steadily over the last decade although it remains illegal in most countries.
PROBLEMS FROM THE START Catherine Moscarello, a former employee of Planet Hospital, said...
Related Articles
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...
By Elise Kinsella, ABC News | 06.15.2025
When *Sarah and her partner needed fertility testing, it was Monash IVF that the pair turned to.
"Having a quick browse online, Monash IVF was one of the most prominent ones that came up on Google search and after contacting...
By Hilary Bowman-Smart and Craig Stanbury, The Conversation | 06.12.2025
By Antonio Regalado, MIT Technology Review | 06.05.2025
Brian Armstrong, the billionaire CEO of the cryptocurrency exchange Coinbase, says he’s ready to fund a US startup focused on gene-editing human embryos. If he goes forward, it would be the first major commercial investment in one of medicine’s most...